Review



volasertib  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress volasertib
    ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors <t>volasertib</t> or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).
    Volasertib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 57 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/volasertib/product/MedChemExpress
    Average 95 stars, based on 57 article reviews
    volasertib - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Multi-omics integration of malignant peripheral nerve sheath tumors identifies potential targets based on chromosome 8q status"

    Article Title: Multi-omics integration of malignant peripheral nerve sheath tumors identifies potential targets based on chromosome 8q status

    Journal: bioRxiv

    doi: 10.64898/2026.01.26.701599

    ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors volasertib or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).
    Figure Legend Snippet: ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors volasertib or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).

    Techniques Used:



    Similar Products

    volasertib  (MedChemExpress)
    95
    MedChemExpress volasertib
    ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors <t>volasertib</t> or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).
    Volasertib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/volasertib/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    volasertib - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    erlotinib  (MedChemExpress)
    95
    MedChemExpress erlotinib
    ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors <t>volasertib</t> or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).
    Erlotinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/erlotinib/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    erlotinib - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    erlotinib hydrochloride  (MedChemExpress)
    93
    MedChemExpress erlotinib hydrochloride
    ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors <t>volasertib</t> or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).
    Erlotinib Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/erlotinib hydrochloride/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    erlotinib hydrochloride - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors volasertib or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).

    Journal: bioRxiv

    Article Title: Multi-omics integration of malignant peripheral nerve sheath tumors identifies potential targets based on chromosome 8q status

    doi: 10.64898/2026.01.26.701599

    Figure Lengend Snippet: ( A-B ) Percent relative cell viability and ( C-D ) IC50 values of MPNST cell lines after 5 days of treatment with either PLK1 inhibitors volasertib or BI-2536 ( A & C ) or EGFR inhibitors erlotinib or osimertinib ( B & D ).

    Article Snippet: Erlotinib, osimertinib, and volasertib were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

    Techniques: